Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00004161 · ClinicalTrials.gov registry record · Phase 2
Fenretinide in Treating Patients With Leukoplakia of the Mouth
A Phase 2 study, sponsored by University of Alabama at Birmingham.
- Completed
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
NCT00004161 is a Phase 2 study that has completed, run by University of Alabama at Birmingham. The registered enrollment target is 30 participants.
The verdict
NCT00004161, a Phase 2 study, has completed, sponsored by University of Alabama at Birmingham.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
Study Summary
RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the development of or treat early cancer. Fenretinide may be an effective drug in treating leukoplakia. PURPOSE: Randomized phase II trial to study the effectiveness of fenretinide in treating patients who have leukoplakia of the mouth.
Interventions
- DRUG Placebo
- DRUG fenretinide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 1997-06 |
| Est. Completion | 2004-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00004161
The ClinicalTrials.gov registry entry for NCT00004161 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Alabama at Birmingham, which has 1,160 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00004161 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00004161 about?
NCT00004161 is a clinical study titled "Fenretinide in Treating Patients With Leukoplakia of the Mouth". RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the development of or treat early cancer. Fenretinide may be an effective drug in treating leukoplakia. PURPOSE: Randomized phase II trial to study the effectiveness of fenretinide in treating patients who have leukopl...
What is the current status of trial NCT00004161?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 1997-06. Estimated completion is 2004-01.
What interventions are being tested in trial NCT00004161?
The interventions under investigation include: Placebo (DRUG), fenretinide (DRUG).
Who is sponsoring clinical trial NCT00004161?
This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.